# Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

> **NCT00548249** · PHASE2 · COMPLETED · sponsor: **Rockwell Medical Technologies, Inc.** · enrollment: 131 (actual)

## Conditions studied

- End-Stage Renal Disease (ESRD)

## Interventions

- **DEVICE:** Standard Bicarbonate Solution
- **DRUG:** Soluble Ferric Pyrophosphate
- **DRUG:** Soluble Ferric Pyrophosphate
- **DRUG:** Soluble Ferric Pyrophosphate
- **DRUG:** Soluble Ferric Pyrophosphate

## Key facts

- **NCT ID:** NCT00548249
- **Lead sponsor:** Rockwell Medical Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-10
- **Final completion:** 2010-01
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548249, "Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00548249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*